Skip to main content

Proteinuria

2
Pipeline Programs
5
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 4 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
1 program
1
valsartanPhase 4Small Molecule1 trial
Active Trials
NCT00241085Completed392Est. Aug 2005
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
ALXN1720Phase 11 trial
Active Trials
NCT05314231Completed13Est. May 2023
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
TCM+ Routine TherapyN/A1 trial
Active Trials
NCT05759754Completed72Est. Dec 2024
Bristol Myers Squibb
1 program
BelataceptPHASE_21 trial
Active Trials
NCT02327403Completed15Est. Oct 2020
Travere Therapeutics
1 program
SparsentanPHASE_41 trial
Active Trials
NCT07219121Active Not Recruiting20Est. May 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Travere TherapeuticsSparsentan
Sandozvalsartan
Bristol Myers SquibbBelatacept
AstraZenecaALXN1720
UNION therapeuticsTCM+ Routine Therapy

Clinical Trials (5)

Total enrollment: 512 patients across 5 trials

NCT07219121Travere TherapeuticsSparsentan

Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis

Start: Oct 2025Est. completion: May 202720 patients
Phase 4Active Not Recruiting
NCT00241085Sandozvalsartan

Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes Mellitus

Start: Nov 2002Est. completion: Aug 2005392 patients
Phase 4Completed
NCT02327403Bristol Myers SquibbBelatacept

Belatacept Conversion in Proteinuric Kidney Transplant Recipients

Start: Oct 2015Est. completion: Oct 202015 patients
Phase 2Completed
NCT05314231AstraZenecaALXN1720

Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria

Start: Jun 2022Est. completion: May 202313 patients
Phase 1Completed
NCT05759754UNION therapeuticsTCM+ Routine Therapy

Effects of Traditional Chinese Medicine (GSJYF) in Children With Inherited Proteinuric Kidney Disease

Start: Sep 2023Est. completion: Dec 202472 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.